David David­son’s R&D odyssey takes him out of blue­bird to an­oth­er biotech start­up with big plans to trans­form ther­a­py

Last year
People

The 20(+1) un­der 40: In­side the next gen­er­a­tion of biotech lead­ers

Last year
Special

Eu­ro­pean Com­mis­sion preps for ma­jor over­haul of phar­ma leg­is­la­tion

Last year
Pharma
FDA+

FDA un­veils top 5 pri­or­i­ties for re­work­ing its Covid-19 re­sponse mov­ing for­ward

Last year
FDA+
Coronavirus

Neil Ku­mar’s Bridge­Bio team locks in a $2.4B part­ner­ship as their next drug gets a snap re­view at the FDA

Last year
Deals

No­var­tis and Genen­tech push for clar­i­ty from FDA on how dis­ease pro­gres­sion mod­els can be used for reg­u­la­to­ry de­ci­sions

Last year
Pharma
FDA+

'Part of re­cov­ery is aware­ness': Pan­dem­ic casts harsh spot­light on in­dus­try-wide lack of di­ver­si­ty in clin­i­cal tri­als

Last year
R&D
In Focus

Ex­clu­sive: Two M&A deals and $9B lat­er, Lon­nie Moul­der is ramp­ing up his lat­est biotech start­up. And this one comes with glob­al vi­sion built in

Last year
Startups

UP­DAT­ED: Bridge­Bio team clears a key hur­dle with their proof-of-con­cept da­ta for a rare ge­net­ic dis­ease. And they can thank the NIH for a quick suc­cess

Last year
R&D

FDA re­quires Re­gen­eron, Lil­ly to mon­i­tor vari­ants as a con­di­tion of mAb EUAs

Last year
FDA+

Next-gen gene edit­ing up­start is grab­bing the brass ring with a $150M crossover play to back its bid on a cure for sick­le cell dis­ease

Last year
Financing
Cell/Gene Tx

UP­DAT­ED: Ru­bius chief lays out the first hu­man da­ta on their lead red cell drug in a come­back play. And the stock sky­rock­ets

Last year
R&D

UP­DAT­ED: Eli Lil­ly touts a 'con­stel­la­tion' of suc­cess­es with their PhII Alzheimer’s study — but dis­ap­point­ing fail­ures drag down shares

Last year
Bioregnum
R&D

Three-day FDA ad­comm to fea­ture un­prece­dent­ed re­view of Mer­ck, Roche and BMS ac­cel­er­at­ed ap­provals

Last year
FDA+

FDA in­spec­tion back­log tops 1,000 — and could last for years — as House hear­ing rais­es se­ri­ous con­cerns

Last year
FDA+
Manufacturing

No­var­tis sues FDA over its stance on Sanofi block­buster’s ex­clu­siv­i­ty

Last year
FDA+

David Liu has a new big idea: pro­teome edit­ing. It could one day shred tau, RAS and some of the worst dis­ease-caus­ing pro­teins

Last year
Discovery
In Focus

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

Last year
Financing
Special

Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

Last year
Deals

Bio­phar­ma's suc­cess rate in bring­ing drugs to mar­ket has long been abysmal. Can new tools help rewrite that trou­bled past?

Last year
In Focus

The $1M IPO bonus, de­cent pay and a nice eq­ui­ty stake to mark the up­side: How does Mark McKen­na's comp pack­age stack up in the Nas­daq rush?

Last year
Financing
Bioregnum

Bio­phar­ma ex­ecs rou­tine­ly shun re­veal­ing the hard truth when it comes to RTFs. And some peo­ple at the FDA think that's a big prob­lem

Last year
Bioregnum
FDA+

The Covid ef­fect has trig­gered some rad­i­cal changes to the top 50 bio­phar­ma list, bring­ing a whole new group of play­ers in­to the big league

Last year
Pharma

Francesco De Ru­ber­tis makes his lega­cy play, re­cruit­ing star ex­ecs and rolling up 10 biotech star­tups in­to a $250M gam­ble on cre­at­ing some­thing new in phar­ma

Last year
Startups
First page Previous page 78910111213 Next page Last page